+

WO2003026490A3 - Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques - Google Patents

Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques Download PDF

Info

Publication number
WO2003026490A3
WO2003026490A3 PCT/US2002/031020 US0231020W WO03026490A3 WO 2003026490 A3 WO2003026490 A3 WO 2003026490A3 US 0231020 W US0231020 W US 0231020W WO 03026490 A3 WO03026490 A3 WO 03026490A3
Authority
WO
WIPO (PCT)
Prior art keywords
bispecific molecules
diagnosis
cancer
treatment
methods
Prior art date
Application number
PCT/US2002/031020
Other languages
English (en)
Other versions
WO2003026490A2 (fr
Inventor
David Jackson
Linda Nardone
Original Assignee
Elusys Therapeutics Inc
David Jackson
Linda Nardone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elusys Therapeutics Inc, David Jackson, Linda Nardone filed Critical Elusys Therapeutics Inc
Priority to EP02778405A priority Critical patent/EP1487487A2/fr
Priority to CA002461631A priority patent/CA2461631A1/fr
Priority to JP2003530136A priority patent/JP2005510470A/ja
Publication of WO2003026490A2 publication Critical patent/WO2003026490A2/fr
Publication of WO2003026490A3 publication Critical patent/WO2003026490A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des molécules bispécifiques présentant une première partie de reconnaissance de l'antigène qui fixe un récepteur de type C3b (connu comme récepteur de complément 1 (CR1) ou CD35 chez les primates), et une seconde partie de reconnaissance de l'antigène qui fixe un antigène associé à une tumeur et présent dans la circulation d'un mammifère. L'invention se rapporte également à des méthodes d'utilisation des molécules bispécifiques pour éliminer de la circulation d'un mammifère les antigènes associés à une tumeur libérés. En outre, l'invention se rapporte à des méthodes d'utilisation de molécules bispécifiques pour le diagnostic et le traitement du cancer.
PCT/US2002/031020 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques WO2003026490A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02778405A EP1487487A2 (fr) 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques
CA002461631A CA2461631A1 (fr) 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques
JP2003530136A JP2005510470A (ja) 2001-09-28 2002-09-27 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32573201P 2001-09-28 2001-09-28
US60/325,732 2001-09-28

Publications (2)

Publication Number Publication Date
WO2003026490A2 WO2003026490A2 (fr) 2003-04-03
WO2003026490A3 true WO2003026490A3 (fr) 2004-10-21

Family

ID=23269190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031020 WO2003026490A2 (fr) 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques

Country Status (4)

Country Link
EP (1) EP1487487A2 (fr)
JP (1) JP2005510470A (fr)
CA (1) CA2461631A1 (fr)
WO (1) WO2003026490A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2006501816A (ja) * 2002-05-13 2006-01-19 エリューシス セラピューティクス，インコーポレーテッド 二重特異性分子の精製組成物および生産方法
CA2543830A1 (fr) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detection d'anticorps anti-therapeutique humain
CA2585849A1 (fr) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Utilisation de molecules de liaison a cr1 dans la clairance et l'induction de reponses immunitaires
JP2008530123A (ja) * 2005-02-09 2008-08-07 ジェネンテック・インコーポレーテッド マトリックスメタロプロテアーゼアンタゴニストを用いたｈｅｒ２のシェディングの阻害
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
EP2365003A1 (fr) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
WO2016161010A2 (fr) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
CA2999138C (fr) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Polypeptides de liaison a cd3
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
HRP20250234T1 (hr) 2018-08-31 2025-04-11 Regeneron Pharmaceuticals, Inc. Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBANELL ET AL: "Inhibition of HER2 Extracellular Domain Shedding by Metalloprotease Inhibitors and by Herceptin[trade] in Breast Cancer Cells", PROC. ANNU. MEET. AM. SOC. CLIN. ONCOL., vol. 18, 1999, pages ABSTRACT A2381, XP002978245 *
TAYLOR ET AL: "Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation", JOURNAL OF HEMATOTHERAPY, vol. 4, no. 5, October 1995 (1995-10-01), pages 357 - 362, XP002978244 *

Also Published As

Publication number Publication date
CA2461631A1 (fr) 2003-04-03
JP2005510470A (ja) 2005-04-21
EP1487487A2 (fr) 2004-12-22
WO2003026490A2 (fr) 2003-04-03

Similar Documents

Publication Publication Date Title
WO2003026490A3 (fr) Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
WO2004018649A3 (fr) Anticorps monoclonaux et regions determinantes de complementarite se liant a des glycoproteine ebola
DK1385864T3 (da) Anti-VEGF-2-antistoffer
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2003020764A3 (fr) Facteur ix modifie
WO2004050707A3 (fr) Molecules de reconnaissance specifiques de tumeurs
IL165267A0 (en) Selected antibodies and duramycin peptides bindingto anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
WO2004074455A3 (fr) Variants de la region fc
WO2002083849A3 (fr) Facteur de croissance endothélial vasculaire 2
IL125590A0 (en) Peptide immunogens
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO2003041736A3 (fr) Methode de traitement de cardiotoxicite induite par des composes anti-tumoraux
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
WO2002081646A3 (fr) Sequences d'epitopes
WO2002088170A3 (fr) Anticorps de blocage cripto et utilisations correspondantes
WO2001036487A3 (fr) Fragments de liaison a l'antigene specifiques aux cellules dendritiques, compositions et methodes d'utilisation, antigenes ainsi reconnus et cellules ainsi obtenues
WO2003061559A3 (fr) Peptides de liaison specifiques au domaine extracellulaire de la proteine erbb2, et utilisations correspondantes
WO2003042247A3 (fr) Anticorps anti-tnf-alpha modifie
EP2124990A4 (fr) Traitements du cancer à base de romidepsine
WO2002077172A3 (fr) Methodes servant a inhiber l'angiogenese, la croissance tumorale et la metastase faisant appel a un anti-il8 et a un anti-muc18 entierement humains dans divers types de tumeurs
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2003001968A8 (fr) Compositions et procedes prohibant l'activation plaquettaire et la thrombose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2461631

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003530136

Country of ref document: JP

Ref document number: 2002340069

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002778405

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002778405

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002778405

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载